Relay Therapeutics announced initial clinical data for RLY-4008 in patients with FGFR2-altered solid tumors, showing promising efficacy signals across multiple tumor types.
AI Assistant
RELAY THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.